Cargando…
Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405060/ https://www.ncbi.nlm.nih.gov/pubmed/36009399 http://dx.doi.org/10.3390/biomedicines10081851 |
_version_ | 1784773787539996672 |
---|---|
author | Trinchieri, Vito Marazzato, Massimiliano Ceccarelli, Giancarlo Lombardi, Francesca Piccirilli, Alessandra Santinelli, Letizia Maddaloni, Luca Vassalini, Paolo Mastroianni, Claudio Maria d’Ettorre, Gabriella |
author_facet | Trinchieri, Vito Marazzato, Massimiliano Ceccarelli, Giancarlo Lombardi, Francesca Piccirilli, Alessandra Santinelli, Letizia Maddaloni, Luca Vassalini, Paolo Mastroianni, Claudio Maria d’Ettorre, Gabriella |
author_sort | Trinchieri, Vito |
collection | PubMed |
description | Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This “real life” study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications. |
format | Online Article Text |
id | pubmed-9405060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94050602022-08-26 Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients Trinchieri, Vito Marazzato, Massimiliano Ceccarelli, Giancarlo Lombardi, Francesca Piccirilli, Alessandra Santinelli, Letizia Maddaloni, Luca Vassalini, Paolo Mastroianni, Claudio Maria d’Ettorre, Gabriella Biomedicines Article Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This “real life” study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications. MDPI 2022-08-01 /pmc/articles/PMC9405060/ /pubmed/36009399 http://dx.doi.org/10.3390/biomedicines10081851 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Trinchieri, Vito Marazzato, Massimiliano Ceccarelli, Giancarlo Lombardi, Francesca Piccirilli, Alessandra Santinelli, Letizia Maddaloni, Luca Vassalini, Paolo Mastroianni, Claudio Maria d’Ettorre, Gabriella Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients |
title | Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients |
title_full | Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients |
title_fullStr | Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients |
title_full_unstemmed | Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients |
title_short | Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients |
title_sort | exploiting bacteria for improving hypoxemia of covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405060/ https://www.ncbi.nlm.nih.gov/pubmed/36009399 http://dx.doi.org/10.3390/biomedicines10081851 |
work_keys_str_mv | AT trinchierivito exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT marazzatomassimiliano exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT ceccarelligiancarlo exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT lombardifrancesca exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT piccirillialessandra exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT santinelliletizia exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT maddaloniluca exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT vassalinipaolo exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT mastroianniclaudiomaria exploitingbacteriaforimprovinghypoxemiaofcovid19patients AT dettorregabriella exploitingbacteriaforimprovinghypoxemiaofcovid19patients |